Blood Cells Count Derived Inflammation Indexes as Predictors of Early Treatment Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis.
IgE
atopic dermatitis
blood cell count
dupilumab
platelet-to-lymphocyte ratio
treatment response
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
07 Mar 2023
07 Mar 2023
Historique:
received:
31
01
2023
revised:
22
02
2023
accepted:
06
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Derived inflammatory indexes from routine hematological parameters might be useful for predicting early-response vs. late/non-response to dupilumab, the first biological agent approved for moderate-to-severe atopic dermatitis (AD). We tested this hypothesis by retrospectively investigating the association between pre-specified baseline inflammatory indexes and dupilumab response (≥50% reduction in the Eczema Area and Severity Index, EASI 50) at 4 and 16 weeks in a consecutive series of 66 AD patients (38 males and 28 females). Forty-six patients (69.7%) were early-responders at 4 weeks, whereas the remaining twenty (30.3%) were late/non-responders at 16 weeks. In logistic regression, the platelet-to-lymphocyte ratio (PLR) was independently associated with early-response (OR = 1.0159, 95% CI 1.0005 to 1.0315,
Identifiants
pubmed: 36983107
pii: jcm12062104
doi: 10.3390/jcm12062104
pmc: PMC10056555
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondo di Ateneo per la Ricerca
ID : Annualità 2019
Références
Dermatol Ther (Heidelb). 2018 Dec;8(4):527-538
pubmed: 30182182
Cancer Immunol Immunother. 2018 Sep;67(9):1349-1353
pubmed: 29947960
J Eur Acad Dermatol Venereol. 2019 Aug;33(8):1562-1568
pubmed: 30959559
World J Surg Oncol. 2020 May 6;18(1):89
pubmed: 32375770
Exp Dermatol. 2001 Feb;10(1):11-8
pubmed: 11168575
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e896-e898
pubmed: 34310749
J Dermatol. 2020 Sep;47(9):1013-1019
pubmed: 32548920
Eur J Clin Invest. 2018 Aug;48(8):e12984
pubmed: 29924383
Br J Cancer. 2012 Aug 7;107(4):695-9
pubmed: 22828611
Nat Rev Dis Primers. 2018 Jun 21;4(1):1
pubmed: 29930242
Perfusion. 2022 May 24;:2676591221090620
pubmed: 35608438
Br J Dermatol. 2019 Nov;181(5):1083-1085
pubmed: 31127860
Lung. 2020 Oct;198(5):821-827
pubmed: 32844257
Curr Med Res Opin. 2016 Oct;32(10):1645-1651
pubmed: 27240604
Med Sci Monit. 2017 Mar 17;23:1340-1346
pubmed: 28306706
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Ther Adv Chronic Dis. 2018 May 11;9(9):159-170
pubmed: 30181845
Br J Dermatol. 2018 May;178(5):1083-1101
pubmed: 29193016
N Engl J Med. 2014 Jul 10;371(2):130-9
pubmed: 25006719
Hum Vaccin Immunother. 2019;15(9):2129-2139
pubmed: 30785362
Mech Ageing Dev. 2022 Jun;204:111674
pubmed: 35421418
N Engl J Med. 2016 Dec 15;375(24):2335-2348
pubmed: 27690741
Clin Exp Med. 2019 Feb;19(1):37-45
pubmed: 30478648
J Dermatolog Treat. 2021 Aug;32(5):507-513
pubmed: 31647347
Eur J Clin Invest. 2019 Jan;49(1):e13037
pubmed: 30316204
J Clin Med. 2020 Mar 13;9(3):
pubmed: 32183179
J Am Acad Dermatol. 2019 Jul;81(1):187-195
pubmed: 30905805
Indian J Dermatol. 2018 Jul-Aug;63(4):305-310
pubmed: 30078874
J Am Acad Dermatol. 2020 May;82(5):1247-1249
pubmed: 31884090
Drugs Context. 2020 Nov 16;9:
pubmed: 33240390
J Dermatol. 2018 Apr;45(4):390-396
pubmed: 29388334
Lancet. 2017 Jun 10;389(10086):2287-2303
pubmed: 28478972
Am J Clin Dermatol. 2018 Aug;19(4):617-624
pubmed: 30027349
Clin Lab. 2022 Feb 1;68(2):
pubmed: 35142203
Br J Surg. 2022 Nov 22;109(12):1206-1215
pubmed: 36130112
Int J Dermatol. 2020 Feb;59(2):253-256
pubmed: 31286499
Am J Clin Dermatol. 2018 Apr;19(2):145-165
pubmed: 29098604
Ocul Immunol Inflamm. 2019;27(6):932-936
pubmed: 29953308
J Am Acad Dermatol. 2019 Jul;81(1):143-151
pubmed: 30825533